Extensive Disease Subtypes in Adult Patients with Ulcerative Colitis: Non-pancolitis Versus Pancolitis

Dong Suk Shin, Jae Hee Cheon, Yong Eun Park, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background and Aim: Few studies have compared pancolitis and non-pancolitis E3 in adult patients with ulcerative colitis (UC). This study aimed to evaluate the natural disease courses and factors affecting outcomes between pancolitis and non-pancolitis E3. Methods: We retrospectively analyzed 117 patients, including 93 with extensive colitis (E3) and 24 with UC confined to the rectum or left-sided colon and appendiceal orifice inflammation at the time of diagnosis, who were regularly followed up for at least 1 year. Patients with E3 were divided into two groups according to the degree of disease extension: pancolitis group (disease extent up to the cecum or proximal ascending colon) and non-pancolitis E3 group (disease extent above the splenic flexure but not up to the proximal ascending colon). Clinical findings at diagnosis; comorbidity; medications; Mayo score; cumulative rates of corticosteroid, immunomodulator, and anti-tumor necrosis factor (anti-TNF) alpha use; relapse; and admission were compared between the pancolitis and non-pancolitis E3 groups. Results: The median follow-up duration of the 117 patients was 74 (range 15–158) months. Fifty-one patients (43.5%) had pancolitis. The Mayo score at initial diagnosis, cumulative relapse rate, and cumulative admission rate were significantly higher in the pancolitis group than in the non-pancolitis E3 group (P < 0.001, P = 0.023 and P = 0.007, respectively). However, there was no significant difference between the groups in the rates of cumulative immunomodulator and anti-TNF alpha use (P = 0.67 and P = 0.73, respectively). Conclusions: In patients with extensive UC (E3), pancolitis was associated with higher probabilities of cumulative relapse or admission, indicating poor prognosis.

Original languageEnglish
Pages (from-to)3097-3104
Number of pages8
JournalDigestive diseases and sciences
Volume63
Issue number11
DOIs
Publication statusPublished - 2018 Nov 1

Fingerprint

Ulcerative Colitis
Ascending Colon
Immunologic Factors
Recurrence
Tumor Necrosis Factor-alpha
Transverse Colon
Cecum
Colitis
Rectum
Comorbidity
Adrenal Cortex Hormones
Colon
Inflammation

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this

Shin, Dong Suk ; Cheon, Jae Hee ; Park, Yong Eun ; Park, Yehyun ; Park, Soo Jung ; Kim, Tae Il ; Kim, Won Ho. / Extensive Disease Subtypes in Adult Patients with Ulcerative Colitis : Non-pancolitis Versus Pancolitis. In: Digestive diseases and sciences. 2018 ; Vol. 63, No. 11. pp. 3097-3104.
@article{f8e2d44f24034e36972fe0d9b0b805c4,
title = "Extensive Disease Subtypes in Adult Patients with Ulcerative Colitis: Non-pancolitis Versus Pancolitis",
abstract = "Background and Aim: Few studies have compared pancolitis and non-pancolitis E3 in adult patients with ulcerative colitis (UC). This study aimed to evaluate the natural disease courses and factors affecting outcomes between pancolitis and non-pancolitis E3. Methods: We retrospectively analyzed 117 patients, including 93 with extensive colitis (E3) and 24 with UC confined to the rectum or left-sided colon and appendiceal orifice inflammation at the time of diagnosis, who were regularly followed up for at least 1 year. Patients with E3 were divided into two groups according to the degree of disease extension: pancolitis group (disease extent up to the cecum or proximal ascending colon) and non-pancolitis E3 group (disease extent above the splenic flexure but not up to the proximal ascending colon). Clinical findings at diagnosis; comorbidity; medications; Mayo score; cumulative rates of corticosteroid, immunomodulator, and anti-tumor necrosis factor (anti-TNF) alpha use; relapse; and admission were compared between the pancolitis and non-pancolitis E3 groups. Results: The median follow-up duration of the 117 patients was 74 (range 15–158) months. Fifty-one patients (43.5{\%}) had pancolitis. The Mayo score at initial diagnosis, cumulative relapse rate, and cumulative admission rate were significantly higher in the pancolitis group than in the non-pancolitis E3 group (P < 0.001, P = 0.023 and P = 0.007, respectively). However, there was no significant difference between the groups in the rates of cumulative immunomodulator and anti-TNF alpha use (P = 0.67 and P = 0.73, respectively). Conclusions: In patients with extensive UC (E3), pancolitis was associated with higher probabilities of cumulative relapse or admission, indicating poor prognosis.",
author = "Shin, {Dong Suk} and Cheon, {Jae Hee} and Park, {Yong Eun} and Yehyun Park and Park, {Soo Jung} and Kim, {Tae Il} and Kim, {Won Ho}",
year = "2018",
month = "11",
day = "1",
doi = "10.1007/s10620-018-5218-x",
language = "English",
volume = "63",
pages = "3097--3104",
journal = "American Journal of Digestive Diseases",
issn = "0002-9211",
publisher = "Springer New York",
number = "11",

}

Extensive Disease Subtypes in Adult Patients with Ulcerative Colitis : Non-pancolitis Versus Pancolitis. / Shin, Dong Suk; Cheon, Jae Hee; Park, Yong Eun; Park, Yehyun; Park, Soo Jung; Kim, Tae Il; Kim, Won Ho.

In: Digestive diseases and sciences, Vol. 63, No. 11, 01.11.2018, p. 3097-3104.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Extensive Disease Subtypes in Adult Patients with Ulcerative Colitis

T2 - Non-pancolitis Versus Pancolitis

AU - Shin, Dong Suk

AU - Cheon, Jae Hee

AU - Park, Yong Eun

AU - Park, Yehyun

AU - Park, Soo Jung

AU - Kim, Tae Il

AU - Kim, Won Ho

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Background and Aim: Few studies have compared pancolitis and non-pancolitis E3 in adult patients with ulcerative colitis (UC). This study aimed to evaluate the natural disease courses and factors affecting outcomes between pancolitis and non-pancolitis E3. Methods: We retrospectively analyzed 117 patients, including 93 with extensive colitis (E3) and 24 with UC confined to the rectum or left-sided colon and appendiceal orifice inflammation at the time of diagnosis, who were regularly followed up for at least 1 year. Patients with E3 were divided into two groups according to the degree of disease extension: pancolitis group (disease extent up to the cecum or proximal ascending colon) and non-pancolitis E3 group (disease extent above the splenic flexure but not up to the proximal ascending colon). Clinical findings at diagnosis; comorbidity; medications; Mayo score; cumulative rates of corticosteroid, immunomodulator, and anti-tumor necrosis factor (anti-TNF) alpha use; relapse; and admission were compared between the pancolitis and non-pancolitis E3 groups. Results: The median follow-up duration of the 117 patients was 74 (range 15–158) months. Fifty-one patients (43.5%) had pancolitis. The Mayo score at initial diagnosis, cumulative relapse rate, and cumulative admission rate were significantly higher in the pancolitis group than in the non-pancolitis E3 group (P < 0.001, P = 0.023 and P = 0.007, respectively). However, there was no significant difference between the groups in the rates of cumulative immunomodulator and anti-TNF alpha use (P = 0.67 and P = 0.73, respectively). Conclusions: In patients with extensive UC (E3), pancolitis was associated with higher probabilities of cumulative relapse or admission, indicating poor prognosis.

AB - Background and Aim: Few studies have compared pancolitis and non-pancolitis E3 in adult patients with ulcerative colitis (UC). This study aimed to evaluate the natural disease courses and factors affecting outcomes between pancolitis and non-pancolitis E3. Methods: We retrospectively analyzed 117 patients, including 93 with extensive colitis (E3) and 24 with UC confined to the rectum or left-sided colon and appendiceal orifice inflammation at the time of diagnosis, who were regularly followed up for at least 1 year. Patients with E3 were divided into two groups according to the degree of disease extension: pancolitis group (disease extent up to the cecum or proximal ascending colon) and non-pancolitis E3 group (disease extent above the splenic flexure but not up to the proximal ascending colon). Clinical findings at diagnosis; comorbidity; medications; Mayo score; cumulative rates of corticosteroid, immunomodulator, and anti-tumor necrosis factor (anti-TNF) alpha use; relapse; and admission were compared between the pancolitis and non-pancolitis E3 groups. Results: The median follow-up duration of the 117 patients was 74 (range 15–158) months. Fifty-one patients (43.5%) had pancolitis. The Mayo score at initial diagnosis, cumulative relapse rate, and cumulative admission rate were significantly higher in the pancolitis group than in the non-pancolitis E3 group (P < 0.001, P = 0.023 and P = 0.007, respectively). However, there was no significant difference between the groups in the rates of cumulative immunomodulator and anti-TNF alpha use (P = 0.67 and P = 0.73, respectively). Conclusions: In patients with extensive UC (E3), pancolitis was associated with higher probabilities of cumulative relapse or admission, indicating poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=85052322327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052322327&partnerID=8YFLogxK

U2 - 10.1007/s10620-018-5218-x

DO - 10.1007/s10620-018-5218-x

M3 - Article

C2 - 30145694

AN - SCOPUS:85052322327

VL - 63

SP - 3097

EP - 3104

JO - American Journal of Digestive Diseases

JF - American Journal of Digestive Diseases

SN - 0002-9211

IS - 11

ER -